Houfková Aneta, Schmidt Monika, Benek Ondřej, Fabrik Ivo, Andrýs Rudolf, Zemanová Lucie, Soukup Ondřej, Musílek Kamil
Faculty of Science, Department of Chemistry, University of Hradec Kralove, Rokitanskeho 62, Hradec Kralove, 500 03, Czech Republic.
Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove, 500 03, Czech Republic.
Alzheimers Res Ther. 2025 Jul 23;17(1):170. doi: 10.1186/s13195-025-01821-8.
The mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (HSD10) is implicated in neurodegenerative disorders, particularly Alzheimer’s disease (AD), through its interplay with the amyloid-β peptide (Aβ). However, its independent pathological role in AD remains unclear.
To explore the individual effects of HSD10 and amyloid precursor protein (APP) overexpression (including the Aβ42-generating APP variant), monoclonal HEK293 cell lines were developed. Cellular fitness was evaluated by measuring ATP levels, cell viability, and cytotoxicity measurements under glucose and galactose culture conditions. Mitochondrial metabolic changes were analysed using mitochondrial electron flow measurements in response to various metabolic substrates. HSD10 enzymatic activity was monitored using a fluorogenic probe, and two HSD10 inhibitors were tested for their ability to reduce cytotoxic effects. Statistical significance was determined using appropriate tests as detailed in the methods section.
The overexpression of HSD10 or APP led to mitochondrial dysfunction and reduced viability, particularly under glucose-deprived conditions. HSD10-driven cytotoxicity was linked to its enzymatic activity and associated with impaired TCA cycle function, reduced β-oxidation, and increased oxidative stress. In contrast, APP overexpression induced Aβ42 production, glucose hypermetabolism, and enhanced β-oxidation. Aβ42 also affected HSD10 activity and further amplified its cytotoxic effects. The benzothiazole-based HSD10 inhibitor restored cell viability under both HSD10 overexpression and Aβ42-rich conditions.
HSD10 and Aβ42 each contribute to mitochondrial impairment via distinct metabolic pathways. These findings established HSD10 as an independent pathological factor in AD and support the potential of HSD10 inhibitors, particularly inhibitor , as therapeutic agents targeting mitochondrial dysfunction in AD.
The online version contains supplementary material available at 10.1186/s13195-025-01821-8.
线粒体酶17β-羟类固醇脱氢酶10型(HSD10)通过与淀粉样β肽(Aβ)相互作用,与神经退行性疾病,特别是阿尔茨海默病(AD)有关。然而,其在AD中的独立病理作用仍不清楚。
为了探究HSD10和淀粉样前体蛋白(APP)过表达(包括产生Aβ42的APP变体)的个体效应,构建了单克隆HEK293细胞系。通过在葡萄糖和半乳糖培养条件下测量ATP水平、细胞活力和细胞毒性来评估细胞适应性。使用线粒体电子流测量法分析对各种代谢底物的反应中线粒体代谢变化。使用荧光探针监测HSD10酶活性,并测试两种HSD10抑制剂降低细胞毒性作用的能力。如方法部分详细所述,使用适当的测试确定统计学意义。
HSD10或APP的过表达导致线粒体功能障碍和活力降低,特别是在葡萄糖缺乏的条件下。HSD10驱动的细胞毒性与其酶活性有关,并与三羧酸循环功能受损、β-氧化减少和氧化应激增加有关。相比之下,APP过表达诱导Aβ42产生、葡萄糖高代谢和增强的β-氧化。Aβ42也影响HSD10活性并进一步放大其细胞毒性作用。基于苯并噻唑的HSD10抑制剂在HSD10过表达和富含Aβ42的条件下均能恢复细胞活力。
HSD10和Aβ42各自通过不同的代谢途径导致线粒体损伤。这些发现确立了HSD10作为AD中的独立病理因素,并支持HSD10抑制剂,特别是抑制剂,作为针对AD中线粒体功能障碍的治疗药物的潜力。
在线版本包含可在10.1186/s13195-025-01821-8获取的补充材料。